SANGAMO THERAPEUTICS, INC. (SGMOQ) Shareholders’ equity 2016–2025
SANGAMO THERAPEUTICS, INC. (SGMOQ) shareholders’ equity at each fiscal year-end, per SEC filings.
-$14.3MFY2025 · since FY2016: $136.2M → -$14.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$14.3M | -162.7% |
| FY2024 | $22.8M | -72.5% |
| FY2023 | $82.9M | -71.9% |
| FY2022 | $295.0M | -21.4% |
| FY2021 | $375.3M | -24.7% |
| FY2020 | $498.2M | +15.2% |
| FY2019 | $432.6M | +18.0% |
| FY2018 | $366.5M | +95.1% |
| FY2017 | $187.9M | +38.0% |
| FY2016 | $136.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SGMOQ financial trends
SGMOQ RevenueSGMOQ Net incomeSGMOQ Net marginSGMOQ Gross profitSGMOQ Gross marginSGMOQ Operating incomeSGMOQ Operating marginSGMOQ Operating cash flowSGMOQ Free cash flowSGMOQ Capital expendituresSGMOQ Return on equitySGMOQ Stock buybacksSGMOQ Dividends paidSGMOQ Total assetsSGMOQ Total liabilitiesSGMOQ overview →